HLA polymorphisms with high expression in multiple sclerosis: systematic review

Leonor Pinheiro , Ana Valado

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004147

PDF (2038KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004147 DOI: 10.37349/ent.2026.1004147
Systematic Review
research-article
HLA polymorphisms with high expression in multiple sclerosis: systematic review
Author information +
History +
PDF (2038KB)

Abstract

Background: Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory disease that affects the central nervous system. Although the true etiology of MS remains unknown, recent research suggests that it arises from a combination of genetic vulnerability and environmental factors. The human leukocyte antigen (HLA) region is a highly polymorphic locus on chromosome 6 encoding antigen-presenting molecules central to adaptive immunity. MS exhibits significant genetic and geographic heterogeneity, reflecting complex interactions between HLA polymorphisms and environmental influences. Risk and protective alleles differ across populations, reinforcing the importance of studying such variations to better understand the disease’s pathogenesis and guide therapeutic strategies. Methods: This systematic review followed the “Preferred Reporting Items for Systematic reviews and Meta-Analyses” (PRISMA) guidelines, and a bibliographic search was conducted in the Medline (PubMed) and Web of Science databases using the keywords “Multiple Sclerosis”, “Genetic Polymorphisms”, “SNPs”, and “Human Leukocyte Antigen”. Results: Twenty-one studies were included, comprising a total of over 50,000 participants across diverse populations. The reviewed studies demonstrate that the alleles DRB1*15:01, DQB1*06:02, DRB1*03:01, DRB1*04:01, DRB1*15:03, DPB1*03:01, as well as the haplotypes DRB1*15:01~ DQB1*06:02 and DRB1*15:01~ DQA1*01:02~ DQB1*06:02, show high expression and are strongly associated with MS susceptibility. In contrast, the alleles A*02:01 and DRB1*01:01 have shown a protective role. Discussion: The evidence confirms a central role of HLA class II alleles and conserved extended haplotypes, particularly DRB1*15:01-containing haplotypes, in MS susceptibility, while highlighting protective alleles and marked variability across ancestral backgrounds. These findings underscore the importance of high-resolution HLA typing, standardized haplotype definitions and inclusion of diverse populations to refine MS risk estimates.

Keywords

multiple sclerosis / genetic polymorphisms / SNPs / human leukocyte antigen

Cite this article

Download citation ▾
Leonor Pinheiro, Ana Valado. HLA polymorphisms with high expression in multiple sclerosis: systematic review. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004147 DOI:10.37349/ent.2026.1004147

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Rispoli MG, Valentinuzzi S, De Luca G, Del Boccio P, Federici L, Di Ioia M, et al. Contribution of Metabolomics to Multiple Sclerosis Diagnosis, Prognosis and Treatment. Int J Mol Sci. 2021; 22: 11112.

[2]

The Multiple Sclerosis International Federation. Atlas of MS, 3rd Edition [Internet]. Multiple Sclerosis International Federation (MSIF); [cited 2025 Apr 18]. Available from: https://www.msif.org/wp-content/uploads/2020/12/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf

[3]

Haase S, Linker RA. Inflammation in multiple sclerosis. Ther Adv Neurol Disord. 2021; 14: 17562864211007687.

[4]

Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018; 391: 1622-36.

[5]

Marrie RA, Fisk JD, Fitzgerald K, Kowalec K, Maxwell C, Rotstein D, et al. Etiology, effects and management of comorbidities in multiple sclerosis: recent advances. Front Immunol. 2023; 14: 1197195.

[6]

De Silvestri A, Capittini C, Mallucci G, Bergamaschi R, Rebuffi C, Pasi A, et al. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2016; 2016: 1409069.

[7]

Haki M, Al-Biati HA, Al-Tameemi ZS, Ali IS, Al-Hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024; 103: e37297.

[8]

Grunwald C, Krętowska-Grunwald A, Adamska-Patruno E, Kochanowicz J, Kułakowska A, Chorąży M. The Role of Selected Interleukins in the Development and Progression of Multiple Sclerosis-A Systematic Review. Int J Mol Sci. 2024; 25: 2589.

[9]

Travers BS, Tsang BK, Barton JL. Multiple sclerosis: Diagnosis, disease-modifying therapy and prognosis. Aust J Gen Pract. 2022; 51: 199-206.

[10]

Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, et al.; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023; 22: 78-88.

[11]

Sarnataro A, Cuomo N, Russo CV, Carotenuto A, Lanzillo R, Moccia M, et al. Integration of the expanded disability status scale with ambulation, visual and cognitive tests. Neurol Sci. 2024; 45: 4799-805.

[12]

Cavallo S. Immune-mediated genesis of multiple sclerosis. J Transl Autoimmun. 2020; 3: 100039.

[13]

Prapas P, Anagnostouli M. Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics. Int J Mol Sci. 2024; 25: 7354.

[14]

Vazifedoust S, Esmaeili Gouvarchin Ghaleh H, Khafaei M, Azemati F, Jalali Kondori B. Comprehensive Assessment of Multiple Sclerosis: From Immunotherapy and Immunopathogenesis to Predictive Biomarkers. Iran J Pathol. 2022; 17: 241-50.

[15]

Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, et al. How patients with multiple sclerosis acquire disability. Brain. 2022; 145: 3147-61.

[16]

Martin R, Sospedra M, Eiermann T, Olsson T. Multiple sclerosis: doubling down on MHC. Trends Genet. 2021; 37: 784-97.

[17]

International Multiple Sclerosis Genetics Consortium; Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357:851-62.

[18]

International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019; 365: eaav7188.

[19]

Manuel AM, Dai Y, Freeman LA, Jia P, Zhao Z. An integrative study of genetic variants with brain tissue expression identifies viral etiology and potential drug targets of multiple sclerosis. Mol Cell Neurosci. 2021; 115: 103656.

[20]

Paramonova N, Trapina I, Dokane K, Kalnina J, Sjakste T, Sjakste N. An Intergenic rs9275596 Polymorphism on Chr. 6p21 Is Associated with Multiple Sclerosis in Latvians. Medicina (Kaunas). 2020; 56: 154.

[21]

Isobe N, Keshavan A, Gourraud PA, Zhu AH, Datta E, Schlaeger R, et al. Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis. JAMA Neurol. 2016; 73: 795-802.

[22]

Vandiedonck C, Knight JC. The human Major Histocompatibility Complex as a paradigm in genomics research. Brief Funct Genomic Proteomic. 2009; 8: 379-94.

[23]

Sorosina M, Santoro S, Ferrè L, Mascia E, Clarelli F, Giordano A, et al. Risk HLA Variants Affect the T-Cell Repertoire in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023; 10:e200093.

[24]

Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021; 372: n160.

[25]

McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021; 12: 55-61.

[26]

Whiting P, Savović J, Higgins JP, Caldwell DM, Reeves BC, Shea B, et al.; ROBIS group. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016; 69: 225-34.

[27]

Asouri M, Alinejad Rokni H, Sahraian MA, Fattahi S, Motamed N, Doosti R, et al. Association of HLA-DRA and IL2RA Polymorphisms with the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population. Rep Biochem Mol Biol. 2020; 9: 129-39.

[28]

Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, et al. Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry. PLoS Genet. 2019; 15: e1007808.

[29]

Fguirouche A, Ouahmani F, Brahim I, Hazime R, Louhab N, Kissani N, et al. Distribution of Major HLA-A, -B, -DR, and -DQ Loci Potentially Associated with Multiple Sclerosis in a Healthy Population from Southern Morocco. Clin Pract. 2025; 15: 10.

[30]

Khdair SI, Al-Khareisha L, Abusara OH, Hammad AM, Khudair A. HLA-class II genes association with multiple sclerosis: An immunogenetic prediction among multiple sclerosis Jordanian patients. PLoS One. 2025; 20: e0318824.

[31]

Beecham AH, Amezcua L, Chinea A, Manrique CP, Gomez L, Martinez A, et al. Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population. PLoS One. 2022; 17: e0279132.

[32]

Goodin DS, Oksenberg JR, Douillard V, Gourraud PA, Vince N. Genetic susceptibility to multiple sclerosis in African Americans. PLoS One. 2021; 16: e0254945.

[33]

Osoegawa K, Creary LE, Montero-Martín G, Mallempati KC, Gangavarapu S, Caillier SJ, et al. High Resolution Haplotype Analyses of Classical HLA Genes in Families With Multiple Sclerosis Highlights the Role of HLA-DP Alleles in Disease Susceptibility. Front Immunol. 2021; 12: 644838.

[34]

Akel O, Zhao LP, Geraghty DE, Lind A. High-resolution HLA class II sequencing of Swedish multiple sclerosis patients. Int J Immunogenet. 2022; 49: 333-9.

[35]

Briggs FBS, Sept C. Mining Complex Genetic Patterns Conferring Multiple Sclerosis Risk. Int J Environ Res Public Health. 2021; 18: 2518.

[36]

Hedström AK, Hillert J, Brenner N, Butt J, Waterboer T, Strid P, et al. DRB1-environment interactions in multiple sclerosis etiology: results from two Swedish case-control studies. J Neurol Neurosurg Psychiatry. 2021; 92: 717-22.

[37]

Barnes CLK, Hayward C, Porteous DJ, Campbell H, Joshi PK, Wilson JF. Contribution of common risk variants to multiple sclerosis in Orkney and Shetland. Eur J Hum Genet. 2021; 29: 1701-9.

[38]

Gontika M, Skarlis C, Artemiadis A, Pons R, Mastroyianni S, Vartzelis G, et al. HLA-DRB1 allele impact on pediatric multiple sclerosis in a Hellenic cohort. Mult Scler J Exp Transl Clin. 2020; 6: 2055217320908046.

[39]

Derdelinckx J, Nkansah I, Ooms N, Van Bruggen L, Emonds MP, Daniëls L, et al. HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients. Cells. 2020; 9: 2703.

[40]

Boullerne AI, Goudey B, Paganini J, Erlichster M, Gaitonde S, Feinstein DL. Validation of tag SNPs for multiple sclerosis HLA risk alleles across the 1000 genomes panel. Hum Immunol. 2024; 85: 110790.

[41]

Mack SJ, Udell J, Cohen F, Osoegawa K, Hawbecker SK, Noonan DA, et al. High resolution HLA analysis reveals independent class I haplotypes and amino-acid motifs protective for multiple sclerosis. Genes Immun. 2019; 20: 308-26.

[42]

Creary LE, Mallempati KC, Gangavarapu S, Caillier SJ, Oksenberg JR, Fernández-Viňa MA. Deconstruction of HLA-DRB1*04:01:01 and HLA-DRB1*15:01:01 class II haplotypes using next-generation sequencing in European-Americans with multiple sclerosis. Mult Scler. 2019; 25: 772-82.

[43]

da Silva Bernardes M, Antão Paiva CL, Ribeiro Paradela E, Papais Alvarenga M, Ferreira Pereira F, Vasconcelos CC, et al. Familial multiple sclerosis in a Brazilian sample: Is HLA-DR15 involved in susceptibility to the disease? J Neuroimmunol. 2019; 330: 74-80.

[44]

Asouri M, Alinejad Rokni H, Sahraian MA, Fattahi S, Motamed N, Doosti R, et al. Analysis of Single Nucleotide Polymorphisms in HLA-DRA, IL2RA, and HMGB1 Genes in Multiple Sclerosis. Rep Biochem Mol Biol. 2020; 9: 198-208.

[45]

Watanabe M, Nakamura Y, Sato S, Niino M, Fukaura H, Tanaka M, et al. HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data. Sci Rep. 2021; 11: 607.

[46]

Ogawa K, Okuno T, Hosomichi K, Hosokawa A, Hirata J, Suzuki K, et al. Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese. J Neuroinflammation. 2019; 16: 162.

[47]

Burnard SM, Lea RA, Benton M, Eccles D, Kennedy DW, Lechner-Scott J, et al. Capturing SNP Association across the NK Receptor and HLA Gene Regions in Multiple Sclerosis by Targeted Penalised Regression Models. Genes (Basel). 2022; 13: 87.

[48]

Falcão AM, van Bruggen D, Marques S, Meijer M, Jäkel S, Agirre E, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med. 2018; 24: 1837-44.

[49]

Buck D, Andlauer TF, Igl W, Wicklein EM, Mühlau M, Weber F, et al.; BEYOND and BENEFIT Study Groups. Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. Mult Scler. 2019; 25: 565-73.

[50]

Hoffmann S, Cepok S, Grummel V, Lehmann-Horn K, Hackermüller J, Stadler PF, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am J Hum Genet. 2008; 83: 219-27.

[51]

Link J, Lundkvist Ryner M, Fink K, Hermanrud C, Lima I, Brynedal B, et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS One. 2014; 9: e90479.

PDF (2038KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉